1 / 2
Orforglipron is an investigational oral medication being developed by Eli Lilly for treating type 2 diabetes and obesity. It is a non-peptide GLP-1 receptor agonist, meaning it mimics the effects of a natural hormone that regulates blood sugar and appetite. Clinical trials have shown that orforglipron can lead to significant weight loss and improved blood sugar control in people with type 2 diabetes and obesity.